Long-lasting severe cytopenia developed in patients treated with BCMA CAR-T therapy. (A) Prevalence of grade ≥3 anemia, thrombocytopenia, and neutropenia at baseline (0) and at 1, 2, 3, and 6 months after infusion of CAR-T treatment. Evolution of aggregate hemoglobin (B), neutrophil (C), and platelet (D) counts from CAR-T infusion up to 1 year of follow-up.